1 Breast Surgery, Herlev and Gentofte Hospital, The Capital Region of Denmark2 unknown
a phase 3 randomised controlled trial
For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.
Lancet Oncology, 2013, Vol 14, Issue 4, p. 297-305